Company Overview of Cosmo Technologies Ltd
Cosmo Technologies Ltd develops oral formulation of mesalamine for first-line treatment for patients with mild to moderate ulcerative colitis. The company was incorporated in 2004 and is based in Dublin, Ireland. Cosmo Technologies Ltd operates as a subsidiary of Cosmo Pharmaceuticals S.p.A.
42-43 Amiens Street
Founded in 2004
353 1 817 0370
Key Executives for Cosmo Technologies Ltd
Cosmo Technologies Ltd does not have any Key Executives recorded.
Cosmo Technologies Ltd Key Developments
Similar Private Companies By Industry
|ADAPT Pharma, Inc.||Europe|
|Bimeda Holdings PLC||Europe|
|Carrick Therapeutics, Ltd.||Europe|
|Consilient Health Ltd.||Europe|
Recent Private Companies Transactions
June 20, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Cosmo Technologies Ltd, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.